Communications to the Editor

Chem. Pharm. Bull. 31(5)1780—1783(1983)

SYNTHESIS OF A NEW POTENT ANTI-ULCER AND GASTRIC SECRETORY INHIBITING AGENT, (-)-cis-2,3-DIHIDRO-3-(4-METHYLPIPERAZINYLMETHYL)-2-PHENYL-1,5-BENZOTHIAZEPIN-4(5H)-ONE HYDROCHLORIDE(BTM-1086), AND RELATED COMPOUNDS

Sachio Ohno, *,a Kihachiro Izumi, a Kiyoshi Mizukoshi, a Kazuo Kato, and Mikio Hori b

Research Laboratories, Maruko Seiyaku Company Ltd., ^a 1212 Teramae, Gejo-Cho, Kasugai 486, Japan and Gifu College of Pharmacy, ^b 5-6-1 Mitahora-Higashi, Gifu 502, Japan

(-)-cis-2,3-Dihydro-3-(4-methylpiperazinylmethyl)-2-phenyl-1,5-benzothiazepin-4(5H)-one hydrochloride(BTM-1086) and its analogues, which possessed potent anti-ulcer and gastric secretory inhibiting activities, were synthesized and the structures of these compounds were established on the basis of spectral and chemical evidences.

KEYWORDS—2,3-dihydro-1,5-benzothiazepin-4(5H)-one; anti-ulcer agent; gastric secretory inhibiting agent; BTM-1086; BTM-1042

Tiazesim($\underline{1}$), $\underline{1}$) an antidepressant agent, and diltiazem($\underline{2}$), $\underline{2}$) a coronary vasodilator, are well known as biologically active compounds having 2,3-dihydro-2-phenyl-1,5-benzothiazepin-4(5H)-one skeleton, and $\underline{2}$ is widely used clinically.

We now report synthesis of (-)-cis-2,3-dihydro-3-(4-methylpiperazinyl-methyl)-2-phenyl-1,5-benzothiazepin-4(5H)-one[(-)-12a, hydrochloride:BTM-1086]^{3,4)} and its analogues with potent anti-ulcer and gastric secretory inhibiting activities.

 $\begin{array}{c|c}
 & CH_2CH_2NMe_2 \\
 & N \\
 & S
\end{array}$ $\begin{array}{c|c}
 & CH_2CH_2NMe_2 \\
 & N \\
 & S
\end{array}$ $\begin{array}{c|c}
 & CH_2CH_2NMe_2 \\
 & N \\
 & S
\end{array}$ $\begin{array}{c|c}
 & OMe
\end{array}$

Treatment of benzylidenemalonates OMe $(\underline{3})^5)$ with 2-aminobenzenethiol afforded addition products $(\underline{4})$ [$\underline{4a}$: 91% yield, mp 70-71°C, δ (CDCl $_3$): 0.93(t, J=7.2 Hz, CH $_2$ CH $_3$), 1.36(t, J=7.2 Hz, CH $_2$ CH $_3$), 3.88(q, J=7.2 Hz, CH $_2$ CH $_3$), 4.02(d, J=11.8 Hz, SCH), 4.15(br, NH $_2$), 4.28(q, J=7.2 Hz, CH $_2$ CH $_3$), 4.06(d, J=11.8 Hz, SCHC \underline{H}), 6.35-6.66(2H, m, Ar H), 6.84-7.26(m, Ar H), 4 \underline{e} : oil]. The esters $(\underline{4})$ were heated in the presence of triethylamine hydrochloride to give trans-amide-esters $(\underline{6})$ [$\underline{6a}$: 44% yield, δ (CDCl $_3$): 1.07(t, J=7.0 Hz, CH $_2$ CH $_3$), 4.02(q, J=7.0 Hz, CH $_2$ CH $_3$), 4.06(d, J=11.2 Hz, C $_3$ -H), 5.13(d, J=11.2 Hz, C $_2$ -H), 7.03-7.72(m, Ar H), 9.13(br s, NH)]. The amide-esters $(\underline{6})$ were also obtained by heating of the mixture of $\underline{3}$, 2-aminobenzenethiol, and triethylamine hydrochloride (6a: 32% yield).

The cyclizations of the esters $(\underline{4})$ and the reactions of the malonates $(\underline{3})$ and 2-aminobenzenethiol yielded by-products, 2-arylbenzothiazoles $(\underline{5})^8$ $(\underline{5a}$: 29 and 32% yield), with the desired compounds $(\underline{6})$.

The esters($\underline{6}$) were reduced to alcohols($\underline{7}$)[$\underline{7a}$: 91% yield, $\delta(\text{CDCl}_3)$: 2.07(s, OH), 2.73-3.83(m, C₃-H and C₃-CH₂), 4.76(d, J=12.0 Hz, C₂-H), 6.90-7.73(m, Ar H), 8.23(br, NH)] with LiAlH₄ in tetrahydrofuran. The alcohols($\underline{7}$) were treated with thionyl chloride, methanesulfonyl chloride, or p-toluenesulfonyl chloride to afford chlorides($\underline{8}$)[$\underline{8a}$: 94% yield, $\delta(\text{CDCl}_3)$: 3.10(dd, J=10.0 and 1.6 Hz, C₃-CHH), 3.40(td, J=11.3 and 1.6 Hz, C₃-H), 4.03(t, J=10.0 Hz, C₃-CHH), 4.37(d, J=11.3 Hz, C₂-H), 7.00-7.80(m, Ar H), 8.30(br s, NH)], mesylates($\underline{9}$)[$\underline{9a}$: 93% yield, $\delta(\text{CDCl}_3)$: 2.87(s, Me), 3.37(td, J=12.0 and 2.5 Hz, C₃-H), 3.73(dd, J=9.3 and 2.5 Hz, C₃-CHH), 4.26(d, J=12.0 Hz, C₂-H), 4.56(t, J=9.3 Hz, C₃-CHH), 6.91-7.70(m, Ar H),

Table. Melting Points(${}^{\circ}$ C) of 2,3-Dihydro-1,5-benzothiazepin-4(5H)-ones($\underline{6}$ - $\underline{12}$)

	R	<u>6</u>	<u>7</u>	<u>8</u>	9	<u>10</u>	<u>11</u>	<u>12</u>
а	Н	198-200	246-248	230-233	213-215	213-215	257-260	203-205
Ъ	4-Me	183-185			205-207		_b)	194-196
С	4-C1	204-206	237-239	238-241 ^{a)}			_b)	245-248 ^{a)}
d	4-0Me	190-192	215-217	231-235 ^a)			_b)	191-193
е	3-Me	175-177	213-216		213-214		207-210	114-117
f	3-C1	195-197	233-236 ^{a)}			192-195	219-222	197-200

a) decomposition. b) not isolated.

8.19(br s, NH)] or tosylates($\underline{10}$)($\underline{10a}$: 88% yield), respectively.

Heating of the compounds (8-10) in N-methylpiperazine gave trans-2-aryl-2,3-dihydro-3-(4-methylpiperazinylmethyl)-1,5-benzothiazepin-4(5H)-ones(11)[11a: 35% yield from 9, δ (CDCl₃): 1.83-2.50(m, C₃-CHH and N(CH₂CH₂)₂N), 2.17(s, Me), 3.00-3.53(m, C₃-H and C₃-CHH), 4.23(br d, J=11.0 Hz, C₂-H), 6.90-7.70(m, Ar H), 8.17 (br, NH)] and the cis-isomers(12)⁹[12a: 39% yield from 9, δ (CDCl₃): 1.83-2.60(m, C₃-CH₂ and N(CH₂CH₂)₂N), 2.20(s, Me), 2.87-3.37(m, C₃-H), 5.07(d, J=6.4 Hz, C₂-H), 6.93-7.73(m, Ar H), 8.70(br, NH)].

The structures of $\underline{11}$ and $\underline{12}$ were established on the basis of NMR spectroscopy and the following reactions.

The pure 11a or 12a changed to the mixture of 11a and 12a by refluxing in N-methylpiperazine(11a/12a=ca. 9). Desulfurization of 11a or 12a with W-7 Raney-cobalt in ethanol afforded the anilide(13)[mp 99-101°C, δ (CDCl₃): 2.00-3.57(m, COCH(CH₂-)₂ and N(CH₂CH₂)₂N), 2.28(s, Me), 6.87-7.80(m, Ar H), 10.72(br, NH)] and treatment of 11a or 12a with sulfuryl chloride in chloroform gave the 2,3-dehydrocompound(14)[mp 219-221°C, δ (CDCl₃): 2.07(s, Me), 1.77-2.50(m, N(CH₂CH₂)₂N), 3.24 (s, C₃-CH₂), 6.93-7.70(m, Ar H), 9.46(br, NH), m/e: 365(M⁺)].

Chart 2

The compound($\underline{14}$) was alternatively synthesized from N-methylpiperazine and the chloride($\underline{15}$) which was prepared from $\underline{8a}$ by treatment with sulfuryl chloride [$\underline{15}$: mp 210-213°C, δ (CDCl₃): 4.33(s, C₃-CH₂), 6.95-7.60(m, Ar H), 9.07(br, NH)].

In the NMR spectra the coupling constants between C_2 -H and C_3 -H of the compounds($\underline{11}$) were larger than those of the compounds($\underline{12}$). For example, the constants of $\underline{11a}$ and $\underline{12a}$ were 11.0 and 6.4 Hz, respectively. This spectral and chemical evidence shows that both $\underline{11}$ and $\underline{12}$ have the 2,3-dihydro-1,5-benzo-thiazepin-4(5H)-one skeleton and that the configurations are trans for $\underline{11}$ and cis for $\underline{12}$. These results are in good agreement with the results obtained in diltiazem($\underline{2}$) and related compounds. 10)

The cis-compounds (12) were optically resolved with tartaric acid in methanol [(-)-12a: mp 196-198°C, $[\alpha]_D^{20}$ -46.0°(c=2.4, CHCl $_3$), hydrochloride(BTM-1086): mp 256-260°C(d), $[\alpha]_D^{20}$ -63.0°(c=2.0, H $_2$ 0), (+)-12a: mp 196-198°C, $[\alpha]_D^{20}$ +46.0°(c=2.4,

CHCl₃)].

The (\pm) and (-)-cis-1,5-benzothiazepin-4(5H)-ones[12 and (-)-12] possessed potent anti-ulcer and gastric anti-secretory activities in biological tests. 3a,4b) For example, (-)-12a had potent inhibition effects on the acute ulcer models such as Shay's ulcers, cold restraint-stress ulcers and serotonin ulcers and on the chronic model such as acetic acid ulcers and also inhibited gastric secretions in pylorus-ligated rats, fistula rats and Shild's rats. The ED₅₀ value of (-)-12a on cold restraint-stress ulcers was 0.1 mg/Kg orally in mice and its activity was 15 times that of atropine. 11) Acute toxicity of (-)-12a was weaker than that of (\pm) or (+)-12a. 3a,4a) The LD₅₀ values of (-) and (\pm)-12a were 870 and 650 mg/Kg orally, and 160 and 65 mg/Kg intravenously, respectively, in mice. 11) BTM-1086 is now under clinical trials.

REFERENCES AND NOTES

- 1) J. Krapcho, E. R. Spitzmiller, and C. F. Turk, J. Med. Chem., <u>6</u>, 544(1963); J. Krapcho, and C. F. Turk, ibid., <u>9</u>, 191(1966).
- 2) a) H. Kugita, H. Inoue, M. Ikezaki, M. Konda, and S. Takeo, Chem. Pharm. Bull., 19, 595(1971); b) H. Inoue, S. Takeo, M. Kawazu, and H. Kugita, Yakugaku Zasshi, 93, 729(1973); c) M. Sato, T. Nagao, I. Yamaguchi, H. Nakajima, and A. Akimoto, Arzneim.-Forsch., 21, 1338(1971).
- 3) a) Ger. Offen., 2,905,637; b) K. Hillier, Drugs Fut., 6, 534(1981).
- 4) a) H. Asai, H. Yamamoto, M. Nagasaka, Y. Nakamura, and M. Fukagawa, The 100th Annual Meeting of The Pharmaceutical Society of Japan, Tokyo, Japan, Apr., 1980, Abstract papers, p. 283; b) H. Yamamoto, J. Miyake, H. Asai, and K. Watanave, ibid., p. 334.
- 5) The benzilidenemalonates $(\underline{3})$ were prepared according to the known method for diethyl benzilidenemalonate $(\underline{3a})$. A part of the compounds $(\underline{3})$ was already described. 7)
- 6) C. F. Allen, and F. W. Spangler, Org. Synth., III, 377(1955).
- 7) For example, E. F. Pratt, and E. Werble, J. Amer. Chem. Soc., <u>72</u>, 4638(1950); Y. Ogata, and M. Tsuchida, ibid., <u>81</u>, 2092(1959); J. Zabicky, J. Chem. Soc., 1961, 683.
- 8) M. T. Bogert, and A. Stull, J. Amer. Chem. Soc., <u>47</u>, 3078(1925); H. Lankelma, and P. X. Sharnoff, ibid., <u>53</u>, 2654(1931); B. Prescott, and J. M. Webb, Antibiot. Chemotherapy, <u>8</u>, 33(1958); M. Hori, T. Kataoka, H. Shimizu, Y. Imai, and H. Fujimura, Yakugaku Zasshi., <u>98</u>, 1019(1978).
- 9) The cis-compounds $(\underline{12})$ were obtained from the trans-compounds $(\underline{8-10})$. We have found that the formation of $\underline{11}$ and $\underline{12}$ proceeded via intermediary ring-opening compounds, and will report in detail in the near future.
- 10) H. Kugita, H. Inoue, M. Ikezaki, M. Konda, and S. Takeo, Chem. Pharm. Bull., 18, 2284(1970); M. Miyazaki, T. Iwakuma, and T. Tanaka, ibid., 26, 2889(1978).
- 11) In these tests, the 1,5-benzothiazepin-4(5H)-ones $[(-)-12a, (\pm)-12a]$ were used as the dihydrochlorides. The dihydrochloride of (-)-12a coded as BTM-1042.

(Received February 28, 1983)